Posted on 11/23/20
How Do Pfizer's and Moderna's COVID Vaccine Results Compare?
We've now heard interim results for two of the leading coronavirus vaccine candidates. Pfizer(NYSE:PFE) and BioNTech(NASDAQ:BNTX) announced initial data for their experimental COVID-19 vaccine BNT162b2 on . . .
Posted on 11/23/20
CVS Health: The Numbers Simply Don't Add Up
SummaryAs a dominant player along the pharmacy value chain, CVS has proven to be a resilient EVA generator through thick and thin.The company is making good . . .
Posted on 11/23/20
What's the Outlook for Moderna Stock?
On Nov. 16, large-cap biotech Moderna (NASDAQ:MRNA) reported that its experimental messenger RNA (mRNA) vaccine (mRNA-1273) is nearly 95% effective at immunizing patients against COVID-19. This . . .
Posted on 11/23/20
Can the Moderna and BioNTech Bulls Keep Running?
Positive results from clinical trials with their coronavirus vaccine candidates have pushed shares of Moderna (NASDAQ:MRNA) and BioNTech (NASDAQ:BNTX) into the clouds. Neither of these companies . . .
Posted on 11/23/20
Warren Buffett Is Throwing Billions at This Stock. Should You Buy, Too?
Berkshire Hathaway (NYSE:BRK-B)(NYSE:BRK-A) chairman and CEO Warren Buffett knows a thing or two about investing, to put it mildly. His investment prowess has helped Berkshire stock . . .
Posted on 11/23/20
Better Coronavirus Stock: Moderna or Novavax?
Does big pharma dominate the coronavirus vaccine race? It might seem that way. Of the five COVID-19 vaccine candidates in late-stage testing that could be players . . .
Posted on 11/23/20
The Big Thing to Know About Moderna's COVID Vaccine Results
Pfizer(NYSE: PFE) and BioNTech(NASDAQ: BNTX) were the first drugmakers to announce interim efficacy results from a late-stage study of their coronavirus vaccine candidate. Moderna(NASDAQ:MRNA) had its . . .
Posted on 11/23/20
Is Moderna a Good Stock to Buy Right Now?
Moderna(NASDAQ:MRNA) recently announced an impressive efficacy of 94.5% from a late-stage study of coronavirus vaccine candidate mRNA-1273. The biotech stock jumped on the good news, but . . .
Posted on 11/23/20
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has . . .
Posted on 11/23/20
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals
F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to transform the lives of patients with cancer through the development . . .
Posted on 11/20/20
Peak Physical Therapy & Sports Performance Expands Clinic at the Wolves Den Sports Complex in Pembroke
Peak Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide comprehensive treatment in orthopedic, spine and sports medicine specialties, has . . .
Posted on 11/20/20
Tufts Health Plan Named a 2020 Top Place to Work by The Boston Globe
Tufts Health Plan has been named one of the Top Places to Work in Massachusetts in the 13th annual employee-based survey from The Boston Globe. Tufts . . .
Posted on 11/20/20
AVROBIO Prices of Underwritten Public Offering of $75 Million of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its . . .
Posted on 11/20/20
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has . . .
Posted on 11/20/20
AVROBIO Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, . . .
Posted on 11/20/20
Stoke Therapeutics Prices $97.5 Million Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein . . .
Posted on 11/19/20
Could Moderna Become the Biggest Vaccine Company in the World Within 4 Years?
Key Points Moderna (NASDAQ:MRNA) CEO Stephane Bancel thinks the biotech could become the world's biggest vaccine company within the next three to four years.The biotech would . . .
Posted on 11/19/20
Moderna's and Pfizer's Vaccine News May Signal a Market Top
This has been a huge month for news, and Wall Street and has been taking in every drop of it. On election night, we learned that . . .
Posted on 11/19/20
What Gives Moderna's Coronavirus Vaccine an Edge?
In this episode of MarketFoolery, Chris Hill chats with Motley Fool analyst Bill Barker about the latest headlines from Wall Street. They discuss what gives Moderna's . . .
Posted on 11/19/20
Is Moderna Still a Compelling Growth Play?
Moderna (NASDAQ:MRNA) has had a banner year in 2020. Thanks to the biotech's COVID-19 vaccine candidate mRNA-1273, the company's shares have gapped up by an eye-catching . . .
Posted on 11/19/20
Stoke Therapeutics Announces Proposed Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein . . .
Posted on 11/18/20
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked . . .
Posted on 11/18/20
Obsidian Therapeutics Collaborates with MD Anderson
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of . . .
Posted on 11/18/20
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
The latest big-ticket acquisition in the healthcare industry has closed. On Tuesday, Bristol Myers Squibb (NYSE:BMY) announced that its buyout of heart medication specialist MyoKardia has . . .
Posted on 11/18/20
Keros Therapeutics Closes Public Offering of Common Stock
LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments . . .
Boston
